<DOC>
	<DOCNO>NCT02044328</DOCNO>
	<brief_summary>Adjuvant therapy prove effective treat early stage less advanced non-small-cell lung cancer . This study design evaluate efficacy icotinib adjuvant therapy treat stage IIA-IIIA adenocarcinoma patient EGFR mutation . The primary endpoint disease-free survival .</brief_summary>
	<brief_title>Icotinib Adjuvant Therapy Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>The patient present operable stage IIAIIIA ( N01 ) lung adenocarcinoma 19 21 exon mutation The patient history anticancer therapy include chemotherapy , radiation therapy The patient ' Eastern Cooperative Oncology Group score â‰¤ 01 The patient sign write informed consent Patients unresected tumor Wild EGFR type Allergic study drug Patients severe noncancerous disease Patients undergo current administration anticancer therapy , attend clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>